Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/7/2009

A via the Special Protocol Assessment process, each in second-line treatment of advanced prostate cancer, featuring either survival or pain palliation as the primary endpoint. We believe these SPA agreements with the FDA together with our Phase 2 survival data position OGX-011 as an attractive asset. These regulatory achievements along with recent clinical data have supported our discussions with potential development and commercialization partners."

Conference Call Today at 4:30 p.m. ET

OncoGenex management will host a conference call at 4:30 p.m. Eastern Time today to provide a business update and discuss the first quarter results. A live webcast will be available through the Events and Presentations Web page found in the Investor Relations section of the OncoGenex Web site at www.ir.oncogenex.com. Alternatively, you may access the live conference call by dialing 800-967-7143 (U.S. & Canada) or 719-325-2413 (International). A webcast replay will be available approximately two hours after the call and will be archived at the same Web location for 90 days.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information about OncoGenex is available at

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
2. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
3. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
4. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
5. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
6. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
7. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
8. OncoGenex Reports Third Quarter Financial Results
9. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... The report “Service Quality Management and Telco ... Type - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” ... and forecasting of revenues. , Browse 152 market ... in-depth TOC on “Service Quality Management (SQM) and Telco ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, ... in critical areas, announced the closing of an underwritten public ... purchase up to an aggregate 3,500,000 shares of common stock, ... per warrant.  The warrants have a per share exercise price ...
(Date:12/24/2014)... BioLife Solutions , Inc. (NASDAQ: BLFS ), a ... hypothermic storage and cryopreservation freeze media and ... ("BioLife" or the "Company"), today announced that it will hold ... (the "Annual Meeting"). Because the expected date for ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn cases ... Syngenta, are in the process of being consolidated in a ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL No. ... Kansas. , Management of the Syngenta GMO corn multidistrict litigation ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... G. Komen for the Cure(R),Tissue Bank at the ... with,BioStorage Technologies, Inc. (BST) for secure, compliant storage ... of the tissue bank,s existing and,future biological samples ... the tissue bank,s upcoming breast tissue,donation event this ...
... WST ) today announced that management will be presenting at two ... CJS Securities, Ninth Annual "New Ideas for the New Year" Conference ... January 7, 2009. , , ... Sidoti & Company,s Sixth Annual Palm Beach Emerging Growth Institutional Investor Forum ...
... Integration Made Simple , ... (PRWEB) December 17, 2008 ... device industry is the modern protocol analyzer, now updated to effortlessly ... glucose monitor and a telephone modem, but also the interface between ...
Cached Biology Technology:BioStorage Technologies Partners with Susan G. Komen for the Cure(R) Tissue Bank at the IU Simon Cancer Center in Breast Cancer Research Initiative 2BioStorage Technologies Partners with Susan G. Komen for the Cure(R) Tissue Bank at the IU Simon Cancer Center in Breast Cancer Research Initiative 3West to Present at Upcoming Conferences 2Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment 2Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment 3
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... of the "Global Wearable Technologies Market and ... Overview, Trends and Forecast 2014-2020" report to ... are smart devices that can be worn on ...
(Date:12/22/2014)... (NASDAQ: NXTD and NXTDW) ("NXT-ID" or the ... commerce market, announces it has retained famous pickpocket, entertainer and ... CES debut of the Wocket™ biometric smart wallet.  ... booth January 6th and 7 th , 2015, demonstrating some ...
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research and Markets ... "Micro Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter security market ... 2014 to 2019. Although the U.S. market holds a larger ...
Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3
... head-and-neck cancers that recur locally after prior full-dose conventional ... These results were obtained in a Phase I/II study ... of the research program, professor Heikki Joensuu, University of ... interesting. They open a new field for BNCT, since ...
... forces? Individuals with chronic myeloid leukemia ... imatinib (Gleevec), which targets the protein known to cause ... mutants emerge that are resistant to the effects of ... dasatinib (SPRYCEL), which targets BCR-ABL in a different way. ...
... memory storage molecule PKMzeta maintains long-term memories ... in order for the memory to endure, according to ... Rehovot, Israel and SUNY Downstate Medical Center in Brooklyn, ... current edition of Science magazine ( www.sciencemag.org ). The ...
Cached Biology News:A new radiation therapy treatment developed for head and neck cancer patients 2JCI table of contents: Aug. 16, 2007 2JCI table of contents: Aug. 16, 2007 3JCI table of contents: Aug. 16, 2007 4JCI table of contents: Aug. 16, 2007 5JCI table of contents: Aug. 16, 2007 6JCI table of contents: Aug. 16, 2007 7
...
...
... III (RNase III) from E. coli is ... (dsRNA) to dsRNA fragments that have 2-base, ... in dsRNA fragments of 12-15 bp. ... of canonical ribonucleotides as well as DuraScript™ ...
Rabbit polyclonal to Peptide E ( Abpromise for all tested applications)....
Biology Products: